Filter By Category
Archives
Share on -
AVOTACICLIB
Generic Name: AVOTACICLIB
ABSTRACT -
Avotaciclib is an orally bioavailable small-molecule cyclin-dependent kinase 1 (CDK1) inhibitor being investigated for potential antineoplastic activity, including settings where tumor cell-cycle control is therapeutically relevant. Its molecular formula is C₁₃H₁₁N₇O, with molecular weight approximately 281.28 g/mol. The chemical representation above shows the 2D skeletal structure.
This document is for structured API information only. It is not a prescribing guide. Clinical use, if any, must follow the approved local label, trial protocol, and specialist medical supervision.
DOSAGE-
- Dosage should be determined only by a qualified healthcare professional or trial investigator.
- Use only according to an approved local label or clinical-trial protocol for the specific indication.
- Dose, schedule, and monitoring may differ by cancer type, combination regimen, organ function, and tolerability.
- Do not change, stop, or restart treatment without specialist medical supervision.
SIDE EFFECTS-
Possible side effects and safety concerns include:
- Gastrointestinal symptoms such as nausea, vomiting, diarrhea, abdominal discomfort, or reduced appetite
- Fatigue, weakness, fever, headache, or general malaise
- Myelosuppression, anemia, neutropenia, thrombocytopenia, or infection risk may occur with cell-cycle inhibitors
- Liver enzyme abnormalities, mucositis, rash, or skin irritation are possible
- Underlying malignancy and combination chemotherapy effects may overlap with drug effects
ALLERGIC REACTIONS -
Hypersensitivity to Avotaciclib or related compounds/products may occur. Symptoms may include:
- Immediate urticaria, itching, flushing, or generalized rash
- Facial, lip, tongue, or throat swelling
- Wheezing, chest tightness, or breathing difficulty
- Dizziness, fainting, severe hypotension, or collapse
- Anaphylaxis, although uncommon, requires emergency medical treatment
Important: Patients who develop an allergic reaction to Avotaciclib should seek immediate medical attention and inform all future healthcare providers of the allergy.
DRUG INTERACTIONS-
Avotaciclib may interact with certain medicines, biologics, vaccines, protocols, or clinical conditions. Caution is needed with:
- Cytotoxic chemotherapy or radiation may increase marrow, mucosal, or gastrointestinal toxicity.
- Other investigational anticancer agents may have additive or unpredictable toxicity.
- Medicines affecting hepatic metabolism or transport should be reviewed before use.
- Patients should report all medicines, supplements, and herbal products.
Patients should inform healthcare providers about all prescription medicines, over-the-counter medicines, herbal products, vaccines, and supplements they are using.
PREAUTIONS–
- Confirm trial eligibility, baseline blood counts, liver function, renal function, and performance status before use.
- Monitor complete blood count, infection symptoms, and adverse events according to protocol.
- Use caution in patients with severe hepatic impairment, uncontrolled infection, or poor marrow reserve.
- Pregnancy and lactation require individualized oncology review.
WARNINGS –
- Investigational anticancer agents may cause severe, delayed, or unexpected toxicity.
- Myelosuppression can lead to serious infection or bleeding complications.
- Use only under oncology supervision and protocol-defined monitoring.
- Keep out of reach of children.
Share on -
. Developed by